PSS and ELITech Group Enter into a Joint Development, Distribution and Supply Agreement on PSS’s “GeneLEAD”, a Fully Automated, Sample-to-result, Real-Time PCR Analyzer

System Science, Co., Ltd. (PSS) and the ELITechGroup (ELITech) announced they have agreed to a Joint Development, Distribution and Supply Agreement in which ELITech’s ELITe MGB Real -Time PCR technology will be optimized and implemented as human in vitro diagnostic tests on the “geneLEAD” system, a fully automated Real-Time PCR analyzer developed by PSS.

PSS has profound experience in automated DNA extraction as represented by its patented Magtration technology. Using this foundation in the molecular diagnostics field, PSS has extended its leadership position with the development of fully automated, sample-to-result Real-Time PCR analyzers. By combining their own technology with PCR and multi-fluorescence assay detection technology, PSS has successfully developed simplified, small footprint and yet high performance automated Real-Time PCR analyzers. Utilizing proven strength in molecular testing consumables, PSS has also developed an efficient straight-line prefilled cartridge for extraction and PCR reagents.

The geneLEAD system has broad applicability in DNA and RNA diagnostic testing such as infectious disease, oncology, and human genetic testing. According to the agreement, geneLEAD will be used for human in vitro diagnostic tests and it well matches the wide portfolio of diagnostic reagents provided by ELITech.

ELITech has a broad array of proven PCR assays currently in use across the world for in vitro diagnostic analysis on open systems. These assays take advantage of ELITech’s intellectual property portfolio which includes the Minor Groove Binder (MGB), modified bases, and novel fluorophores. The panel of assays cover a broad spectrum of tests for infectious disease, oncology and human genetics applications.

Pierre Debiais, CEO ELITech commented “The combination of PSS unique expertise in systems development, in particular in Molecular Diagnostics, and ELITech’s unique IP portfolio and broad range of assays will deliver a timely attractive molecular platform”.
“The process of molecular diagnostic testing is complex and customer’s needs are widely diverse. The right instrument, the right reagents as well as experience with these products in the field are indispensable to be successful and meet customer expectations. The agreement between PSS and ELITech provides a novel business model that delivers unique solutions for molecular diagnostics testing” said Hideji Tajima, President PSS.